Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
Jeffrey A. Cohen, Robert A Bermel, Cynthia Grossman, et al.
Multiple Sclerosis Journal (2022) Vol. 28, Iss. 7, pp. 1131-1137
Open Access | Times Cited: 18

Showing 18 citing articles:

Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability
Alise Carlson, Moein Amin, Jeffrey A. Cohen
Drugs (2024) Vol. 84, Iss. 3, pp. 285-304
Open Access | Times Cited: 15
Clinical opinions and case studies on understanding and managing hypogammaglobulinaemia in multiple sclerosis: United Kingdom perspective
Sharmilee Gnanapavan, Angray S. Kang, David Baker, et al.
Multiple Sclerosis and Related Disorders (2025) Vol. 96, pp. 106353-106353
Open Access
Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes
Kathryn B. Holroyd, Brian C. Healy, Sarah Conway, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 67, pp. 104079-104079
Open Access | Times Cited: 20
Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs
Rocco Capuano, Luca Prosperini, Manuela Altieri, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 7, pp. 856-865
Open Access | Times Cited: 10
Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity
Nicole Bou Rjeily, Kathryn C. Fitzgerald, Ellen M. Mowry
Multiple Sclerosis Journal (2023) Vol. 30, Iss. 2, pp. 257-260
Closed Access | Times Cited: 10
COVID-19: The Course, Vaccination and Immune Response in People with Multiple Sclerosis: Systematic Review
Marcin Bazylewicz, Monika Gudowska-Sawczuk, Barbara Mroczko, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9231-9231
Open Access | Times Cited: 5
Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies
Ronen Spierer, Idit Lavi, Sivan Bloch, et al.
Journal of Neurology (2023) Vol. 270, Iss. 10, pp. 4632-4639
Closed Access | Times Cited: 4
Era of COVID-19 in Multiple Sclerosis Care
Jonathan D. Krett, Amber Salter, Scott D. Newsome
Neurologic Clinics (2023) Vol. 42, Iss. 1, pp. 319-340
Open Access | Times Cited: 4
Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence
Sajida Sabsabi, Elio Mikhael, Georges Jalkh, et al.
Patient Preference and Adherence (2022) Vol. Volume 16, pp. 1307-1319
Open Access | Times Cited: 7
Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab
Jacqueline Nicholas, Mark Gudesblatt, Meghan Garabedian, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 63, pp. 103921-103921
Open Access | Times Cited: 5
SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis
Bruce Cree, Rachel Maddux, Amit Bar‐Or, et al.
Annals of Clinical and Translational Neurology (2023) Vol. 10, Iss. 10, pp. 1725-1737
Open Access | Times Cited: 2
Vaccine response in people with multiple sclerosis treated with fumarates
Matthew Tremblay, Sandra Vukusic, Mathura Shanmugasundaram, et al.
Multiple Sclerosis Journal - Experimental Translational and Clinical (2023) Vol. 9, Iss. 3
Open Access | Times Cited: 2
Two years of COVID-19 in the MS community: What have we learnt so far?
Ana Zabalza, Alan J. Thompson, Xavier Montalbán
Multiple Sclerosis Journal (2022) Vol. 28, Iss. 7, pp. 1005-1008
Open Access | Times Cited: 3
COVID-19 in Patients with Multiple Sclerosis – A narrative review
Bijay Kumar Shrestha, Eru Sujakhu, Smruti Karale, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 93, pp. 106221-106221
Closed Access
Natalizumab as a high-efficacy therapy with proven confirmed long-term effectiveness and a new, subcutaneous administration formula
Monika Adamczyk‐Sowa
Aktualności Neurologiczne (2023) Vol. 22, Iss. 4, pp. 207-210
Open Access | Times Cited: 1
Intensive Aerobic Cycling Is Feasible and Elicits Improvements in Gait Velocity in Individuals With Multiple Sclerosis: A Preliminary Study
Sarah B. Simmons, Alexis Skolaris, Ryan J. Love, et al.
International Journal of MS Care (2023) Vol. 26, Iss. 3, pp. 119-124
Open Access | Times Cited: 1
Immune response to COVID-19 vaccines in patients with multiple sclerosis treated with disease-modifying therapies
Waldemar Brola
Neurologia i Neurochirurgia Polska (2022) Vol. 57, Iss. 1, pp. 11-13
Open Access | Times Cited: 2
Humoral immune response after Ad26.COV2.S vaccination in patients with multiple sclerosis treated with natalizumab
Mark Gudesblatt, Myassar Zarif, Barbara Bumstead, et al.
Multiple Sclerosis Journal - Experimental Translational and Clinical (2023) Vol. 9, Iss. 4
Open Access
Page 1

Scroll to top